Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer
ChemMedChem · 2026
DOI: 10.1002/cmdc.202501111 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, 2026. Verfasst von Chao Tang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Weiyang University Park, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Receptors, Estrogen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 92 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shaanxi Administration of Traditional Chinese Medicine, Science and Technology Department of Shaanxi Province.
Abstract (Originalsprache)
Vepdegestrant (ARV‐471) is an orally bioavailable, proteolysis‐targeting chimera (PROTAC)‐based estrogen receptor (ER) degrader and is among the most clinically advanced ER‐targeting PROTAC degraders, identified through a rational medicinal chemistry optimization campaign. It is being developed as an oral small‐molecule endocrine therapy for advanced or metastatic ER‐positive, human epidermal growth factor receptor 2 (HER2)‐negative breast cancer, with particular relevance for tumors harboring ESR1 mutations. On June 6, 2025, Arvinas and Pfizer submitted a New Drug Application (NDA) for vepdegestrant to the U.S. Food and Drug Administration (FDA), representing an important step in the clinical translation of PROTAC technology. This review summarizes the design, synthesis, degradation mechanism, preclinical pharmacology, and clinical development of vepdegestrant and discusses the broader implications and future prospects of oral PROTAC‐based ER degraders in breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological and Pharmaceutical Sciences, Shaanxi University of Science & Technology, Weiyang University Park, Xi'an, Shaanxi, China.
- Xi'an Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Therapeutics Research, Weiyang University Park, Xi'an, Shaanxi, China.
- Xixian New Area Fenghou Original Medical Technology Co.Ltd., Xixian Financial Port, Energy and Financial Trade Zone, Xi'an, Shaanxi, China.
- Zhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Guangdong Medical University, Zhanjiang, Guangdong, China.
- Xi'an Taikomed Pharmaceutical Technology Co.Ltd., Xi'an, Shaanxi, China.
ORCID-Profile: Chengyuan Liang, Lei Tian
Förderung
- National Natural Science Foundation of China
- Shaanxi Administration of Traditional Chinese Medicine
- Science and Technology Department of Shaanxi Province
- the Xi'an Science and Technology Project
- the Xianyang Science and Technology Project
- the Xi'an Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Therapeutics Research
- Shaanxi Provincial Department of Education Industrialization Cultivation Project
- Shaanxi Provincial Department of Education University Engineering Research Center Project
Zitieren
APA
Tang, C., Tian, B., Zhang, B., Zhang, Y., Ke, C., Chen, M., Wei, M., Wang, W., Deng, X., Zhang, Q., Wang, M., Xia, J., He, M., Liang, C., & Tian, L. (2026). Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer. ChemMedChem. https://doi.org/10.1002/cmdc.202501111
Vancouver
Tang C, Tian B, Zhang B, Zhang Y, Ke C, Chen M, et al. Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer. ChemMedChem. 2026. doi:10.1002/cmdc.202501111
BibTeX
@article{Tang2026,
author = {Tang, Chao and Tian, Bin and Zhang, Bingxing and Zhang, Yunfei and Ke, Changhua and Chen, Mengxin and Wei, Meiyan and Wang, Wen and Deng, Xintao and Zhang, Qiannan and Wang, Mengzhou and Xia, Juan and He, Meiling and Liang, Chengyuan and Tian, Lei},
title = {Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202501111}
}
EUVIMED